^
    16d
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466
    16d
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov)
    P2, N=200, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • SHR-A2102 • AiRuiLi (adebrelimab)
    17d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • GSK5764227
    1m
    A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination with Other Antitumor Therapies in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (ChiCTR2500110933)
    P2, N=366, Recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    3ms
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • SHR-A2102 • AiRuiLi (adebrelimab)
    3ms
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=351, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • garetatug rezetecan (SHR-A1904)
    4ms
    SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    zeprumetostat (SHR-2554)
    4ms
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=351, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • garetatug rezetecan (SHR-A1904)
    5ms
    EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. (PubMed, Cell Death Dis)
    We inferred that STAT1 was the key driver of the synergistic effect using RNA-seq and ChIP-seq analysis. Our findings provide sufficient preclinical evidence in support of a potential combination therapy strategy for TCL patients.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554)
    5ms
    Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donors. (PubMed, Int Immunopharmacol)
    SHR2554 significantly attenuated CD107a expression and IFNγ/TNFα secretion from CD3+/CD4+/CD8+ T cells, thereby suppressing polyfunctional responses across T cell subsets SHR2554, a potent and highly selective small-molecule inhibitor of EZH2, demonstrated a remarkable anti-proliferative effect on donor peripheral blood T cells, and modified T cell ratios and suppressed their polyfunctional responses. SHR2554 therefore has potential for treating graft-versus-host disease.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    zeprumetostat (SHR-2554)
    1year
    Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial • Combination therapy
    |
    zeprumetostat (SHR-2554) • Itari (linperlisib)
    1year
    SHR-1701 Combined with SHR2554 and BP102 for MCRC (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)